Keyphrases
Breast Cancer
59%
Tumor
23%
Epithelial Cell Adhesion Molecule (EpCAM)
23%
Breast Cancer Patients
22%
Mammaglobin
21%
Neoantigen
19%
T Cells
18%
Early Breast Cancer
18%
Vaccination
17%
Dendritic Cells
17%
Pancreatic Cancer
16%
Human Breast Cancer
15%
Tumor Immunity
15%
CD8+ T Cells
14%
Metastatic Breast Cancer
13%
Breast Reconstruction
13%
Quantitative PCR
13%
Sentinel Lymph Node
12%
Molecular Detection
11%
Sentinel Lymph Node Biopsy
11%
Cancer Neoantigens
11%
Axillary Ultrasound
11%
Cancer Immunotherapy
10%
Ductal Carcinoma in Situ
10%
Pathological Complete Response
9%
Axillary Lymph Node
9%
Antigen-specific
9%
Pancreatic Ductal Adenocarcinoma
9%
DNA Vaccine
9%
Neoadjuvant Chemotherapy
9%
CD8+ T Cell Response
9%
CD8+
8%
Triple-negative Breast Cancer
8%
Micrometastatic
8%
Antigen-specific T Cell Response
8%
Peripheral Blood
8%
Multimarker
8%
Neoantigen Vaccine
8%
Pancreatic Adenocarcinoma
8%
Breast
7%
HDR Brachytherapy
7%
Neoadjuvant
7%
Dendritic Cell Subsets
7%
Metastasis
7%
Mastectomy
7%
CDC1
6%
Multi-institutional
6%
Programmed Death-ligand 1 (PD-L1)
6%
Lymph Node
6%
Cancer Peptide Vaccine
6%
Medicine and Dentistry
Breast Cancer
100%
Neoplasm
40%
Malignant Neoplasm
26%
Metastatic Carcinoma
17%
Disease
16%
Axillary Lymph Node
15%
Recurrent Disease
15%
Quadrantectomy
13%
Sentinel Lymph Node
12%
Sentinel Lymph Node Biopsy
12%
Pancreas Adenocarcinoma
12%
Epithelial Cell Adhesion Molecule
11%
Mastectomy
10%
T Cell
10%
Lymph Node
9%
Metastatic Breast Cancer
9%
Antigen Specificity
9%
Neoadjuvant Chemotherapy
9%
Cytotoxic T-Cell
8%
Interstitial Brachytherapy
8%
Tumor Cell
8%
Micrometastasis
7%
Intraductal Carcinoma
7%
Quantitative Reverse Transcription Polymerase Chain Reaction
7%
Surgery
7%
Pancreas Cancer
7%
Clinical Trial
6%
Radiation Therapy
6%
Primary Tumor
6%
Thyroidectomy
6%
Mammaglobin A
6%
Fine-Needle Aspiration
6%
Drug Megadose
6%
Cytokine
6%
Overall Survival
6%
T-Cell Response
6%
Mammography
6%
Histopathology
5%
Tumor Progression
5%
Molecular Marker
5%
Prognostic Factor
5%
Cohort Analysis
5%
Papillary Thyroid Cancer
5%
Prospective Cohort Study
5%